Clinical Trial Update: First in Man Evaluation of Single and Multiple Doses of Oral ATX2417 [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study evaluating single and multiple oral doses of ATX2417 has been completed. The trial was sponsored by Atopix Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases

Drugs mentioned

• ATX2417

Snippet

Sponsor: Atopix Therapeutics, Ltd. | Conditions: Allergy | Phase 1 | Status: COMPLETED